Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

304 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer.
Blagden S, Omlin A, Josephs D, Stavraka C, Zivi A, Pinato DJ, Anthoney A, Decordova S, Swales K, Riisnaes R, Pope L, Noguchi K, Shiokawa R, Inatani M, Prince J, Jones K, Twelves C, Spicer J, Banerji U. Blagden S, et al. Among authors: twelves c. Clin Cancer Res. 2014 Dec 1;20(23):5908-17. doi: 10.1158/1078-0432.CCR-14-1315. Epub 2014 Sep 17. Clin Cancer Res. 2014. PMID: 25231405 Free PMC article. Clinical Trial.
'Tablet burden' in patients with metastatic breast cancer.
Milic M, Foster A, Rihawi K, Anthoney A, Twelves C. Milic M, et al. Among authors: twelves c. Eur J Cancer. 2016 Mar;55:1-6. doi: 10.1016/j.ejca.2015.11.015. Epub 2015 Dec 28. Eur J Cancer. 2016. PMID: 26734784
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours.
de Bono J, Lin CC, Chen LT, Corral J, Michalarea V, Rihawi K, Ong M, Lee JH, Hsu CH, Yang JC, Shiah HS, Yen CJ, Anthoney A, Jove M, Buschke S, Fuertig R, Schmid U, Goeldner RG, Strelkowa N, Huang DC, Bogenrieder T, Twelves C, Cheng AL. de Bono J, et al. Among authors: twelves c. Br J Cancer. 2020 Apr;122(9):1324-1332. doi: 10.1038/s41416-020-0774-1. Epub 2020 Mar 12. Br J Cancer. 2020. PMID: 32161368 Free PMC article. Clinical Trial.
Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study.
Albertella MR, Loadman PM, Jones PH, Phillips RM, Rampling R, Burnet N, Alcock C, Anthoney A, Vjaters E, Dunk CR, Harris PA, Wong A, Lalani AS, Twelves CJ. Albertella MR, et al. Among authors: twelves cj. Clin Cancer Res. 2008 Feb 15;14(4):1096-104. doi: 10.1158/1078-0432.CCR-07-4020. Clin Cancer Res. 2008. PMID: 18281542 Free article. Clinical Trial.
A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma.
Rampling R, Peoples S, Mulholland PJ, James A, Al-Salihi O, Twelves CJ, McBain C, Jefferies S, Jackson A, Stewart W, Lindner J, Kutscher S, Hilf N, McGuigan L, Peters J, Hill K, Schoor O, Singh-Jasuja H, Halford SE, Ritchie JW. Rampling R, et al. Among authors: twelves cj. Clin Cancer Res. 2016 Oct 1;22(19):4776-4785. doi: 10.1158/1078-0432.CCR-16-0506. Epub 2016 May 25. Clin Cancer Res. 2016. PMID: 27225692 Free PMC article. Clinical Trial.
304 results